Moderna-Merck vaccine data

Lifestyle · Heat 10.0 / 10 · 5 shows · 15m airtime

Moderna and Merck released full phase three data on October 22, 2026 for their personalized mRNA cancer vaccine, intismeran, in melanoma. Combined with Keytruda, it cut the risk of recurrence or death by 42% over two years and distant spread or death by 38% versus Keytruda alone, with a 33% decline in death. Coverage splits on whether 42% clears investor expectations. The discussion has since moved to what comes next: a kidney cancer readout is expected at the end of the year or early next year, with lung cancer framed as the big test.

How 5 podcasts covered it

1. Closing Bell, 2026-10-22 (23:19 to 24:37)
   Reports the full phase three numbers
   Reports the full phase three numbers after a partial leak: the vaccine plus Keytruda cut melanoma recurrence or death by 42% and distant spread or death by 38%, with detailed results due Saturday in Spain.
   New angle: The vaccine plus Keytruda cut melanoma recurrence or death by 42% and distant spread or death by 38%.
2. Closing Bell, 2026-10-22 (32:32 to 34:21)
   Reports the phase three melanoma vaccine numbers
   Reports the detailed phase three numbers for Moderna and Merck's melanoma vaccine ahead of Saturday's conference presentation, and reads the 17% drop as a sell-the-news reaction against sky-high expectations rather than a verdict on the data.
   New angle: The vaccine plus Keytruda cut melanoma recurrence or death 42% and distant spread or death 38% versus Keytruda alone.
3. Morning Brew Daily, 2026-10-23 (22:39 to 24:33)
   Reports the leaked melanoma vaccine data
   Covers the leaked Moderna melanoma vaccine results and the market reaction: a 42% reduction in recurrence risk that clears regulators but falls short of blockbuster expectations, sending shares down.
   New angle: The personalized mRNA melanoma vaccine cut cancer recurrence risk by 42%, below investor expectations.
4. Global News Podcast, 2026-10-23 (12:02 to 14:56)
   Reports the trial through one patient and her doctor
   Reports the trial result through one patient and the Cambridge doctor who ran that site: the 42% two-year reduction, the mRNA tailoring to each tumour, and the open questions on long-term evidence and cost.
   New angle: The personalised mRNA melanoma vaccine cut recurrence or death risk by 42% over two years alongside Keytruda.
5. Squawk Pod, 2026-10-23 (11:05 to 13:31)
   Reads the melanoma data as sell-the-news
   Covers the leaked and then released melanoma data and the 17 percent sell-off, reading the drop as sell-the-news and noting the 42 percent recurrence-or-death reduction and 33 percent decline in death.
   New angle: The melanoma immunotherapy cut recurrence or death risk 42 percent versus Keytruda alone, with a 33 percent decline in death.
6. The Readout Loud, 2026-10-30 (1:55 to 4:15)
   Walks through the 42% progression reduction
   Walks through the ESMO readout of the intismeran-Keytruda data: the 42% reduction in disease progression versus Keytruda alone in adjuvant melanoma, and the debate over how broadly personalized cancer vaccines will work. A retelling of the disclosed numbers, with the vaccine's name and the conference setting added.
7. The Readout Loud, 2026-10-30 (4:15 to 6:09)
   Adds the cost and access questions
   Turns to cost and access: Keytruda's decade as standard of care, copycat versions due in a few years, and the vaccine's expected hefty price tag. Drew's sit-down with Bancel adds the pipeline map - kidney cancer data at year-end or early next year, lung cancer as the big test.
   New angle: The next intismeran readout is in kidney cancer at the end of the year or early next year; lung cancer is the big test.